Lally DR - Search Results

1

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.

Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Among authors: lally dr. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275

2

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.

Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Patel SS, et al. Among authors: lally dr. Eye (Lond). 2023 Dec;37(17):3551-3557. doi: 10.1038/s41433-023-02497-w. Epub 2023 Mar 24. Eye (Lond). 2023. PMID: 36964259 Free PMC article. Clinical Trial.

3

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.

Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Patel SS, et al. Among authors: lally dr. Eye (Lond). 2023 Dec;37(17):3705. doi: 10.1038/s41433-023-02548-2. Eye (Lond). 2023. PMID: 37237234 Free PMC article. No abstract available.

4

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.

Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Among authors: lally dr. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.

5

Vision loss reduction with avacincaptad pegol for geographic atrophy: a 12-month post hoc analysis of the GATHER1 and GATHER2 trials.

Danzig CJ, Khanani AM, Kaiser PK, Chang M, Kovach JL, Lally DR, Rachitskaya A, Sheth VS, Vajzovic L, Clark J, Tang J, Zhu L, Desai D, Chakravarthy U. Danzig CJ, et al. Among authors: lally dr. Ophthalmol Retina. 2024 May 6:S2468-6530(24)00224-0. doi: 10.1016/j.oret.2024.04.023. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38719191

6

CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH USE OF AMYL NITRITE "POPPERS".

Lam A, Gulati S, Foster BS, Lally DR. Lam A, et al. Among authors: lally dr. Retin Cases Brief Rep. 2024 Jan 1;18(1):138-140. doi: 10.1097/ICB.0000000000001338. Retin Cases Brief Rep. 2024. PMID: 36007175

7

Evaluation of a self-imaging SD-OCT system designed for remote home monitoring.

Kim JE, Tomkins-Netzer O, Elman MJ, Lally DR, Goldstein M, Goldenberg D, Shulman S, Benyamini G, Loewenstein A. Kim JE, et al. Among authors: lally dr. BMC Ophthalmol. 2022 Jun 10;22(1):261. doi: 10.1186/s12886-022-02458-z. BMC Ophthalmol. 2022. PMID: 35689210 Free PMC article.

8

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Lally DR, et al. Eye (Lond). 2023 Jun;37(8):1748. doi: 10.1038/s41433-022-02130-2. Eye (Lond). 2023. PMID: 35676464 Free PMC article. No abstract available.

9

Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.

Lally DR, Hill L, Amador-Patarroyo MJ. Lally DR, et al. Ophthalmol Retina. 2022 Nov;6(11):1054-1060. doi: 10.1016/j.oret.2022.05.026. Epub 2022 May 30. Ophthalmol Retina. 2022. PMID: 35654363 Free article. Clinical Trial.

10

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Lally DR, et al. Eye (Lond). 2023 Apr;37(6):1242-1248. doi: 10.1038/s41433-022-02092-5. Epub 2022 May 21. Eye (Lond). 2023. PMID: 35597816 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page